Invivyd, Inc. (IVVD)
NASDAQ: IVVD · Real-Time Price · USD
0.9346
+0.0202 (2.21%)
At close: Jun 23, 2026, 4:00 PM EDT
0.9500
+0.0154 (1.65%)
After-hours: Jun 23, 2026, 7:22 PM EDT
Invivyd Employees
Invivyd had 122 employees as of December 31, 2025. The number of employees increased by 22 or 22.00% compared to the previous year.
Employees
122
Change (1Y)
22
Growth (1Y)
22.00%
Revenue / Employee
$457,918
Profits / Employee
-$636,066
Market Cap
275.34M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 122 | 22 | 22.00% | 122 | 0 |
| Dec 31, 2024 | 100 | 5 | 5.26% | 99 | 1 |
| Dec 31, 2023 | 95 | 9 | 10.47% | 94 | 1 |
| Dec 31, 2022 | 86 | -17 | -16.50% | 84 | 2 |
| Dec 31, 2021 | 103 | - | - | 101 | 2 |
Related Stocks
| Company Name | Employees |
|---|---|
| Bicycle Therapeutics | 288 |
| Lyell Immunopharma | 161 |
| Nautilus Biotechnology | 127 |
| Niagen Bioscience | 117 |
| Neumora Therapeutics | 92 |
| SAB Biotherapeutics | 86 |
| Lineage Cell Therapeutics | 77 |
| Cartesian Therapeutics | 75 |
IVVD News
- 7 days ago - Invivyd completes enrollment of LIBERTY clinical trial - TheFly
- 7 days ago - Invivyd Announces Completion of Enrollment in Phase 3 LIBERTY Trial Evaluating VYD2311 Antibody Versus mRNA COVID-19 Vaccine - GlobeNewsWire
- 14 days ago - Invivyd Announces First Participants Dosed in LIBERTY, a Phase 3 Clinical Trial to Evaluate the Safety and Tolerability of VYD2311 Antibody Versus mRNA COVID Vaccine and to Characterize the Safety and Immunology of Antibody and mRNA Vaccine Co-Administration - GlobeNewsWire
- 15 days ago - Invivyd Transcript: H.C. Wainwright “HCW @ Home” Series - Transcripts
- 20 days ago - Invivyd Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 20 days ago - Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 22 days ago - Invivyd completes enrollment in DECLARATION trial - TheFly
- 22 days ago - Invivyd Announces Completion of Enrollment in Upsized DECLARATION Clinical Trial, a Phase 3 Pivotal Study of VYD2311, an Investigational Antibody to Prevent COVID - GlobeNewsWire